Education
About Us
Working with TipRanks
Follow Us
Percheron Therapeutics Limited (PERCF)
:PERCF
PERCF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.01 - $0.06
Previous CloseN/A
Volume44.70K
Average Volume (3M)333.00
Market Cap
$6.40M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,087,437,600
10 Day Avg. Volume1,000
30 Day Avg. Volume333
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$0.01Price Target Upside0.00%
Rating ConsensusHold
Number of Analyst Covering0
Percheron Therapeutics News
PremiumCompany Announcements
Percheron Therapeutics Updates Stakeholders on HMBD-002 and Financials
PremiumCompany Announcements
Percheron Therapeutics Secures License for Promising Cancer Drug HMBD-002
PremiumCompany Announcements
Percheron Therapeutics Initiates Trading Halt Ahead of Licensing Announcement
PremiumCompany Announcements
Percheron Therapeutics Announces Director’s Interest Change
PremiumCompany Announcements
Percheron Therapeutics Updates Director’s Securities Interest
PremiumCompany Announcements
Percheron Therapeutics Announces Loyalty Options Offer to Shareholders
PremiumCompany Announcements
Percheron Therapeutics Announces Bonus Issue of SecuritiesOptions Prices
Currently, No data available
---
Ownership Overview
PERCF FAQ
What was Percheron Therapeutics Limited’s price range in the past 12 months?
Percheron Therapeutics Limited lowest stock price was $0.01 and its highest was $0.06 in the past 12 months.
What is Percheron Therapeutics Limited’s market cap?
Percheron Therapeutics Limited’s market cap is $6.40M.
When is Percheron Therapeutics Limited’s upcoming earnings report date?
Percheron Therapeutics Limited’s upcoming earnings report date is Aug 27, 2025 which is in 59 days.
How were Percheron Therapeutics Limited’s earnings last quarter?
Percheron Therapeutics Limited released its earnings results on Feb 19, 2025. The company reported -$0.006 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.004.
Is Percheron Therapeutics Limited overvalued?
According to Wall Street analysts Percheron Therapeutics Limited’s price is currently same.
Does Percheron Therapeutics Limited pay dividends?
Percheron Therapeutics Limited does not currently pay dividends.
What is Percheron Therapeutics Limited’s EPS estimate?
Percheron Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Percheron Therapeutics Limited have?
Percheron Therapeutics Limited has 1,087,437,600 shares outstanding.
What happened to Percheron Therapeutics Limited’s price movement after its last earnings report?
Percheron Therapeutics Limited reported an EPS of -$0.006 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Percheron Therapeutics Limited?
Currently, no hedge funds are holding shares in PERCF
Percheron Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.01 (0.00% )
$0.01 (0.00% )
Blogger Sentiment
Bullish
PERCF Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $91.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-100.19%
Trailing 12-Months
Asset Growth
-18.60%
Trailing 12-Months
Company Description
Percheron Therapeutics Limited
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.